Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2007

View Archived Issues

Recent Bayer patents report novel therapeutic agents for urological disorders

New agents for treating neurological disorders disclosed in recent patent literature

New therapeutic strategies for cancer imparted in recent patents

BENCHMRK studies reveal activity of raltegravir in triple-class resistant HIV

Interleukin-12 gene therapy safe in phase I ovarian cancer study

Maraviroc effective in phase IIb/III studies in CCR5-tropic HIV-1

rAAV HIV vaccine safe, well tolerated in healthy subjects

Entecavir selects for HIV resistance mutations

Idenix develops potent and selective anti-HIV agents

Treatment complete in phase II osteoarthritis study of Indaflex

MIV-701 begins clinical studies for osteoporosis

Novartis Consumer Health to copromote Vusion ointment to U.S. pediatricians

Encouraging proof-of-concept results for PA-325

Enrollment complete in phase I/II study of ALKS-29 in alcohol dependence

Financing at TransOral to support Intermezzo NDA filing

Enrollment completed in phase II study of CTA-018 for psoriasis

Sinovac updates progress of pandemic influenza vaccine study

Sunesis studies SNS-032 for advanced B-cell malignancies in clinic

Phase II study of faropenem in acute otitis media meets primary objective

Panzem NCD studied with Sutent in metastatic renal cell carcinoma

Roche's HPV tests accepted for FDA review

Enrollment completed in phase IIb study of AeroLEF

Sankyo and Biota license Hovione's inhaler technology for influenza

Amarin acquires rights to nasal lorazepam for emergency epilepsy seizures

Target enrollment reached in phase III trials of Puricase

Flurizan shows benefit in mild Alzheimer's patients

Topline MERLIN TIMI-36 results for ranolazine

Moli-1901 improves lung function in cystic fibrosis study

Lipitor approved for five new indications in heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...